The SWOG Statistical and Data Management Center (SDMC) plays a vital role in SWOG's overall mission to direct and participate in clinical trials tht will lead to effective treatment and prevention of cancer and to improve quality of life for cancer patients and survivors. The SDMC provides statistical leadership and data management expertise in the design, implementation, monitoring, analysis and interpretation of clinical trials and translational medicine studies. Key SDMC goals include the following: a) to design and implement statistically rigorous and efficient clinical trials;b) to carefully monitor ongoing trils and use state-of-the-art statistical analysis methods to analyze and interpret study results;c) to conduct statistical methods research in clinical trial design and analysis, and the analysis of translational medicine studies;d) to develop systems and utilize technologies for high quality and timely collection, review, storage and retrieval of clinical and biologic data;e) to educate SWOG investigators and other oncology research professionals in leading edge scientific design, statistical techniques and data management methods;f) to evaluate novel strategies for the efficient collection of specific types of patient data including electronic medical record (EMR and web-based methods;and g) to be a dynamic member of the NCTN by providing a wealth of experience and leadership for NCTN endeavors such as steering committees and working groups. The SWOG SDMC contributes meaningfully to the goals of SWOG within the NCTN to provide generalizable, high quality and efficient strategies that can be used by other clinical trials organizations and researchers in the conduct of oncology clinical trials and analysis of associated biologic studies.
Well designed and conducted clinical trials are the primary means for improving therapy for cancer, advancing the chance for cure and increasing the length and quality of life of patients. The SWOG SDMC aims to be a leader in the field through efficient and high-quality design, management, and analysis of these trials, thereby helping to ensure that the results of clinical trials have the greatest potential impact on cancer patients.
|Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146|
|Halpern, Anna B; Othus, Megan; Huebner, Emily M et al. (2018) Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia :|
|Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888|
|Smith, Eileen P; Li, Hongli; Friedberg, Jonathan W et al. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant 24:700-707|
|Unger, Joseph M; Vaidya, Riha; Gore, John L (2018) Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. Urol Oncol :|
|Cheng, Ting-Yuan David; Darke, Amy K; Redman, Mary W et al. (2018) Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst 110:734-742|
|West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92|
|Walter, Roland B; Michaelis, Laura C; Othus, Megan et al. (2018) Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol 93:E49-E52|
|Othus, Megan; Estey, Elihu H; Garcia-Manero, Guillermo et al. (2018) Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. Leukemia :|
|Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504|
Showing the most recent 10 out of 156 publications